{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:32:28Z","timestamp":1783996348924,"version":"3.55.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejim.2023.12.026","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T06:48:22Z","timestamp":1705819702000},"page":"23-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Resistant hypertension: Diagnosis, evaluation, and treatment practical approach"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4426-4126","authenticated-orcid":false,"given":"Roberto","family":"Parodi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Brandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejim.2023.12.026_bib0001","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1097\/HJH.0000000000001961","article-title":"2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH\/ESC Task Force for the Management of Arterial Hypertension","volume":"36","author":"Williams","year":"2018","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2023.12.026_bib0002","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"issue":"6","key":"10.1016\/j.ejim.2023.12.026_bib0003","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"38","author":"Unger","year":"2020","journal-title":"J Hypertens"},{"issue":"6","key":"10.1016\/j.ejim.2023.12.026_bib0004","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"22","key":"10.1016\/j.ejim.2023.12.026_bib0005","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.12.026_bib0006","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2023.12.026_bib0007","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/HYPERTENSIONAHA.113.02026","article-title":"Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort","volume":"63","author":"Calhoun","year":"2014","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.ejim.2023.12.026_bib0008","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1751-7176.2011.00556.x","article-title":"Refractory hypertension: definition, prevalence, and patient characteristics","volume":"14","author":"Acelajado","year":"2012","journal-title":"J Clin Hypertens"},{"issue":"11","key":"10.1016\/j.ejim.2023.12.026_bib0009","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1097\/HJH.0000000000002913","article-title":"Prognostic value of masked uncontrolled apparent resistant hypertension detected through home blood pressure monitoring","volume":"39","author":"Barochiner","year":"2021","journal-title":"J Hypertens"},{"issue":"3","key":"10.1016\/j.ejim.2023.12.026_bib0010","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/ehjcvp\/pvz057","article-title":"Hypertension resistant hypertension: new insights and therapeutic perspectives","volume":"6","author":"Ruilope","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"11","key":"10.1016\/j.ejim.2023.12.026_bib0011","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1097\/00004872-200111000-00018","article-title":"High prevalence of cardiac and extracardiac target organ damage in refractory hypertension","volume":"19","author":"Cuspidi","year":"2001","journal-title":"J Hypertens"},{"issue":"6","key":"10.1016\/j.ejim.2023.12.026_bib0012","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/hr.2013.30","article-title":"Resistant hypertension and target organ damage","volume":"36","author":"Muiesan","year":"2013","journal-title":"Hypertens Res"},{"issue":"13","key":"10.1016\/j.ejim.2023.12.026_bib0013","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2023.12.026_bib0014","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/eci.12565","article-title":"Ambulatory blood pressure monitoring in daily clinical practice\u2014the Spanish ABPM Registry experience","volume":"46","author":"Gorostidi","year":"2016","journal-title":"Eur J Clin Invest"},{"issue":"11","key":"10.1016\/j.ejim.2023.12.026_bib0015","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/jch.12886","article-title":"Untreated, uncontrolled, and apparent resistant hypertension: results of the German health examination survey 2008-2011","volume":"18","author":"Sarganas","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"10.1016\/j.ejim.2023.12.026_bib0016","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cjca.2011.12.012","article-title":"Factors associated with lack of awareness and uncontrolled high blood pressure among Canadian adults with hypertension","volume":"28","author":"Gee","year":"2012","journal-title":"Can J Cardiol"},{"issue":"10","key":"10.1016\/j.ejim.2023.12.026_bib0017","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.mayocp.2013.06.017","article-title":"Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system","volume":"88","author":"Sim","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.ejim.2023.12.026_bib0018","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/jch.12433","article-title":"Resistant hypertension: risk factors, subclinical atherosclerosis, and comorbidities among adults-the Brazilian Longitudinal Study of Adult Health (ELSABrasil)","volume":"17","author":"Lotufo","year":"2015","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"10.1016\/j.ejim.2023.12.026_bib0019","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/ajh\/hpu151","article-title":"Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations","volume":"28","author":"Achelrod","year":"2015","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ejim.2023.12.026_bib0020","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/jhh.2016.6","article-title":"Prevalence and determinants of resistant hypertension in a sample of patients followed in Italian hypertension centers: results from the MINISAL-SIIA study program","volume":"30","author":"Galletti","year":"2016","journal-title":"J Hum Hypertens"},{"issue":"2","key":"10.1016\/j.ejim.2023.12.026_bib0021","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","article-title":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients","volume":"105","author":"Noubiap","year":"2019","journal-title":"Heart"},{"issue":"7","key":"10.1016\/j.ejim.2023.12.026_bib0022","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1161\/CIRCRESAHA.118.312156","article-title":"Treatment of resistant and refractory hypertension","volume":"124","author":"Acelajado","year":"2019","journal-title":"Circ Res"},{"issue":"9","key":"10.1016\/j.ejim.2023.12.026_bib0023","first-page":"e430","article-title":"Refractory versus resistant hypertension: novel distinctive phenotypes","volume":"3","author":"Dudenbostel","year":"2017","journal-title":"J Nat Sci"},{"issue":"3","key":"10.1016\/j.ejim.2023.12.026_bib0024","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/jch.13196","article-title":"Refractory hypertension focus on nighttime blood pressure and nondipping","volume":"20","author":"Cuspidi","year":"2018","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"5","key":"10.1016\/j.ejim.2023.12.026_bib0025","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1161\/01.HYP.0000016176.16042.2F","article-title":"Resistant hypertension: comparing hemodynamic management to specialist care","volume":"39","author":"Taler","year":"2002","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.ejim.2023.12.026_bib0026","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","article-title":"Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion","volume":"168","author":"Gaddam","year":"2008","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1016\/j.ejim.2023.12.026_bib0027","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1097\/HJH.0000000000001106","article-title":"Copeptin is increased in resistant hypertension","volume":"34","author":"Mendes","year":"2016","journal-title":"J Hypertens"},{"issue":"2","key":"10.1016\/j.ejim.2023.12.026_bib0028","first-page":"57","article-title":"Management of resistant hypertension: do not give up on medication","volume":"13","author":"Judd","year":"2014","journal-title":"Nephrol Self Assess Program"},{"key":"10.1016\/j.ejim.2023.12.026_bib0029","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1161\/HYPERTENSIONAHA.115.05155","article-title":"Global- and renal-specific sympathoinhibition in aldosterone hypertension","volume":"65","author":"Lohmeier","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2023.12.026_bib0030","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ejim.2023.12.026_bib0031","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.hipert.2019.07.001","article-title":"Impact of cognitive biases in therapeutic inertia in arterial hypertension: not everything is as it seems","volume":"37","author":"Sabio","year":"2020","journal-title":"Hipertens Riesgo Vasc"},{"issue":"5","key":"10.1016\/j.ejim.2023.12.026_bib0032","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","article-title":"Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring","volume":"57","author":"de la","year":"2011","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.ejim.2023.12.026_bib0033","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1097\/HJH.0b013e3283652c61","article-title":"Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis","volume":"31","author":"Strauch","year":"2013","journal-title":"J Hypertens"},{"issue":"2","key":"10.1016\/j.ejim.2023.12.026_bib0034","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/HYPERTENSIONAHA.112.192096","article-title":"The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension","volume":"60","author":"Daugherty","year":"2012","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.ejim.2023.12.026_bib0035","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1751-7176.2012.00690.x","article-title":"Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension","volume":"14","author":"Irvin","year":"2012","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"1","key":"10.1016\/j.ejim.2023.12.026_bib0036","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pcad.2019.11.012","article-title":"Impact of therapeutic lifestyle changes in resistant hypertension","volume":"63","author":"Ozemek","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"issue":"15","key":"10.1016\/j.ejim.2023.12.026_bib0037","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1161\/CIRCULATIONAHA.121.055329","article-title":"Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial","volume":"144","author":"Bumenthal","year":"2021","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ejim.2023.12.026_bib0038","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjhyper.2005.01.002","article-title":"Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension","volume":"18","author":"Nishizaka","year":"2005","journal-title":"Am J Hypert"},{"key":"10.1016\/j.ejim.2023.12.026_bib0039","doi-asserted-by":"crossref","first-page":"f1325","DOI":"10.1136\/bmj.f1325","article-title":"Effect of longer term modest salt reduction on blood pressure: cochrane systematic review and meta-analysis of randomised trials","volume":"346","author":"He","year":"2013","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ejim.2023.12.026_bib0040","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/HYPERTENSIONAHA.109.131235","article-title":"Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial","volume":"54","author":"Pimenta","year":"2009","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.ejim.2023.12.026_bib0041","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1161\/HYPERTENSIONAHA.111.179788","article-title":"Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension","volume":"58","author":"Pedrosa","year":"2011","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.ejim.2023.12.026_bib0042","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2337\/dc07-0031","article-title":"Primary aldosteronism in diabetic subjects with resistant hypertension","volume":"30","author":"Umpierrez","year":"2007","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ejim.2023.12.026_bib0043","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","article-title":"Hyperaldosteronism among black and white subjects with resistant hypertension","volume":"40","author":"Calhoun","year":"2002","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.ejim.2023.12.026_bib0044","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/HJH.0b013e328360ddf6","article-title":"Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China","volume":"31","author":"Sang","year":"2013","journal-title":"J Hypertens"},{"issue":"3","key":"10.1016\/j.ejim.2023.12.026_bib0045","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/HYPERTENSIONAHA.119.14359","article-title":"Screening rates for primary aldosteronism in resistant hypertension: a cohort study","volume":"75","author":"Jaffe","year":"2020","journal-title":"Hypertension"},{"issue":"21","key":"10.1016\/j.ejim.2023.12.026_bib0046","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1001\/jama.2014.5180","article-title":"Resistant hypertension: a review of diagnosis and management","volume":"311","author":"Vongpatanasin","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ejim.2023.12.026_bib0047","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1161\/HYPERTENSIONAHA.114.05021","article-title":"Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects","volume":"65","author":"Roush","year":"2015","journal-title":"Hypertension"},{"issue":"26","key":"10.1016\/j.ejim.2023.12.026_bib0048","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1056\/NEJMoa2212270","article-title":"Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events","volume":"387","author":"Areef Ishani","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2023.12.026_bib0049","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.hipert.2017.11.004","article-title":"Current status of noninvasive hemodynamics in hypertension","volume":"35","author":"Waisman","year":"2018","journal-title":"Hipertens Riesgo Vasc"},{"issue":"12","key":"10.1016\/j.ejim.2023.12.026_bib0050","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1097\/HJH.0000000000000749","volume":"33","author":"Elmula","year":"2015","journal-title":"Hypertens"},{"key":"10.1016\/j.ejim.2023.12.026_bib0051","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ejim.2023.12.026_bib0052","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","article-title":"The role of spironolactone in the treatment of patients with refractory hypertension","volume":"15","author":"Ouzan","year":"2002","journal-title":"Am J Hypertens"},{"issue":"7","key":"10.1016\/j.ejim.2023.12.026_bib0053","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.amjhyper.2005.11.016","article-title":"Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension","volume":"19","author":"Sharabi","year":"2006","journal-title":"Am J Hypertens"},{"issue":"4","key":"10.1016\/j.ejim.2023.12.026_bib0054","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/HJH.0b013e328014954d","article-title":"Low-dose spironolactone in the management of resistant hypertension: a surveillance study","volume":"25","author":"Lane","year":"2007","journal-title":"J Hypertens"},{"issue":"1","key":"10.1016\/j.ejim.2023.12.026_bib0055","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","article-title":"Efficacy of spironolactone therapy in patients with true resistant hypertension","volume":"55","author":"de Souza","year":"2010","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.ejim.2023.12.026_bib0056","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jash.2008.05.005","article-title":"Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension","volume":"2","author":"Calhoun","year":"2008","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.ejim.2023.12.026_bib0057","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","article-title":"Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT). A randomized, double-blind, placebo-controlled trial","volume":"57","author":"V\u00e1clav\u00edk","year":"2011","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.ejim.2023.12.026_bib0058","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/ajh\/hpv031","article-title":"The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies","volume":"28","author":"Dahal","year":"2015","journal-title":"Am J Hypertens"},{"issue":"10008","key":"10.1016\/j.ejim.2023.12.026_bib0059","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejim.2023.12.026_bib0060","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/HYPERTENSIONAHA.117.10662","article-title":"ReHOT Investigators. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (Resistant Hypertension Optimal Treatment)","volume":"71","author":"Krieger","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2023.12.026_bib0061","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1161\/HYPERTENSIONAHA.122.19280","article-title":"Comparative safety and effectiveness of aldosterone antagonists versus beta-blockers as fourth agents in patients with apparent resistant hypertension","volume":"79","author":"Desai","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2023.12.026_bib0062","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/HJH.0000000000003330","article-title":"Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes","volume":"41","author":"Agarwal","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2023.12.026_bib0063","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","article-title":"FIDELIO-DKD Investigators Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes","volume":"79","author":"Ruilope","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2023.12.026_bib0064","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"FIDELIO-DKD and FIGARO-DKD investigators Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.12.026_bib0065","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.12.026_bib0066","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"FIGARO-DKD Investigators Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.12.026_bib0067","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ejim.2023.12.026_bib0068","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(21)01640-8","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"399","author":"Shi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2023.12.026_bib0069","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/HYPERTENSIONAHA.118.12290","article-title":"Effects of bariatric surgery versus medical therapy on the 24-hour ambulatory blood pressure and the prevalence of resistant hypertension","volume":"73","author":"Schiavon","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2023.12.026_bib0070","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2337\/dc18-2207","article-title":"Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide","volume":"42","author":"Georgianos","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2023.12.026_bib0071","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","article-title":"Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction","volume":"42","author":"Jackson","year":"2021","journal-title":"Eur Heart J"},{"issue":"10367","key":"10.1016\/j.ejim.2023.12.026_bib0072","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ejim.2023.12.026_bib0073","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of Baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.12.026_bib0074","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","article-title":"RADIANCE-HTN investigators Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial","volume":"397","author":"Azizi","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2023.12.026_bib0075","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/eurheartj\/ehad054","article-title":"Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Cardiovascular Interventions (EAPCI)","volume":"44","author":"Barbato","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.12.026_bib0076","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","article-title":"RADIANCE-HTN Investigators. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial","volume":"391","author":"Azizi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2023.12.026_bib0077","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","article-title":"SPYRAL HTN-OFF MED Pivotal Investigators. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicenter, randomised, sham-controlled trial","volume":"395","author":"Bohm","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2023.12.026_bib0078","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1093\/eurheartj\/ehz118","article-title":"Effects of renal denervation on kidney function and long-term outcomes: 3- year follow-up from the Global SYMPLICITY Registry","volume":"40","author":"Mahfoud","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.12.026_bib0079","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.jacc.2022.08.802","article-title":"Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range","volume":"80","author":"Mahfoud","year":"2022","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523004612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523004612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T19:00:19Z","timestamp":1715108419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523004612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":79,"alternative-id":["S0953620523004612"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.12.026","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistant hypertension: Diagnosis, evaluation, and treatment practical approach","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.12.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}